Observational studyInternal medicine (Tokyo, Japan)2022
Safety Profile of Ixazomib in Patients with Relapsed/Refractory Multiple Myeloma in Japan: An All-case Post-marketing Surveillance.
Yoshihide Kakimoto et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.